Cresco Labs OTC ( (CRLBF) ) has released its Q3 earnings. Here is a breakdown of the information Cresco Labs OTC presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cresco Labs Inc. is a leading company in the cannabis industry, known for its branded cannabis products and Sunnyside dispensaries, operating across multiple markets in the United States. The company focuses on cultivation, production, and distribution of cannabis products, aiming to professionalize the industry through a consumer-packaged goods approach.
In its latest earnings report for the third quarter of 2025, Cresco Labs reported a revenue of $165 million and an operating cash flow of $6 million. Despite a net loss of $22 million, the company maintained its market leadership and highlighted its strategic initiatives, including debt refinancing and expansion into new markets.
Key financial metrics from the report include a gross profit of $79 million and an adjusted EBITDA of $40 million, with an adjusted gross margin of 48.8% and an adjusted EBITDA margin of 24.1%. The company also announced its expansion plans with new dispensaries in Ohio and Kentucky, and a product launch in Germany, which are expected to drive future growth.
Looking ahead, Cresco Labs is positioning itself to lead in the evolving cannabis market through scale, efficiency, and disciplined execution. The company’s management remains optimistic about creating long-term shareholder value by leveraging its core assets and operational excellence.